Normunity CEO Rachel Humphrey and founder Lieping Chen
Normunity nabs $75M Series B to advance T cell engager and launch first trial
A startup from PD-L1 pioneer Lieping Chen has closed a new financing round.
Normunity raised $75 million in a Series B …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
